Due to the significant prevalence of lymphopenia in COVID-19 patients and its strong correlation with disease severity, current research suggests that lymphocyte count, particularly CD4+ levels, can be employed as a predictive biomarker for disease severity. This evidence concerns the gene CD4 and COVID-19.